LOZOL
INDAPAMIDE
Approval overview LOZOL is listed in Drugs@FDA under application 018538 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient INDAPAMIDE Form and strength TABLET;ORAL - 2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor SANOFI AVENTIS US Submission history Latest submission status date: 2021-03-02 00:00:00.
Structured Monograph
Clinical summary
Approval overview LOZOL is listed in Drugs@FDA under application 018538 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient INDAPAMIDE Form and strength TABLET;ORAL - 2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor SANOFI AVENTIS US Submission history Latest submission status date: 2021-03-02 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.